TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited

Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Central District of California on behalf of a class (the “Class”) consisting of persons and entities that purchased or otherwise acquired Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE: TEVA) securities between February 10, 2014 and November 3, 2016, inclusive (the “Class Period”).

If you are a member of the Class described above, you may move the Court no later than January 5, 2017, to serve as lead plaintiff. Please contact Lesley Portnoy at 888-773-9224 or 310-201-9150, or at [email protected] to discuss this matter.

On November 3, 2016, Bloomberg published the article “U.S. Charges in Generic-Drug Probe to Be Filed by Year End” which discussed the Department of Justice’s two year investigation of suspected price collusion by several pharmaceutical companies, including Teva, which will likely result in prosecutors filing criminal charges by the end of the year.

The complaint filed in this lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva and several of its pharmaceutical industry peers colluded to fix generic drug prices; (2) the foregoing conduct constituted a violation of federal antitrust laws; (3) consequently, Teva’s revenues during the Class Period were in part the result of illegal conduct; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.

If you purchased shares of Teva during the Class Period you may move the Court no later than January 5, 2017 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to [email protected], or visit our website at www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
27/12/2016

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

Si Yong Ng
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: Teva

Haidje Rustau ... (+5)
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Virgin Media O2, Italmatch Chemicals, Trivium, Air Baltic, Travelodge, Teva

 PRESS RELEASE

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth ...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 bill...

 PRESS RELEASE

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease w...

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’ Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD programHD is a rare, progressive genetic disorder often described as a combination of ALS, Parkinson’s and Alzheimer’s, which manifests in motor, cognitive, and emotional symptoms1Teva’s Honestly HD program provides educational information about HD chorea, a symptom occurring in up to 90% of people with HD,2 to help those living with the condition and their care...

 PRESS RELEASE

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and ...

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and adult patients.1,2Results from the SPACE trial found AJOVY significantly reduced monthly migraine days and monthly headache days versus placebo over a 12-week period in p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch